News Releases

These are news releases that are related to our company, pipeline and investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools below.

Nov 4, 2015

Summary Toggle Publication in Nature Demonstrates Physiocrine Genetic Mutation Disrupts A Key Signaling Pathway in Neuronal Biology

aTyr Sponsored Research For New Target For Rare Hereditary Peripheral Neuropathies SAN DIEGO , Nov. 4, 2015 / PRNewswire / -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe rare
Nov 3, 2015

Summary Toggle aTyr Pharma to Present at 24th Annual Credit Suisse Healthcare Conference

SAN DIEGO , Nov. 3, 2015 / PRNewswire / -- aTyr Pharma (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address rare diseases, today announced the Company's participation at the 24 th Annual Credit Suisse Healthcare Conference
Oct 13, 2015

Summary Toggle aTyr Pharma Initiates Phase 1b/2 Clinical Trial for Patients with Limb Girdle Muscular Dystrophy 2B

SAN DIEGO , Oct. 13, 2015 / PRNewswire / -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe rare diseases, today announced expansion of its Resolaris™ clinical program in rare myopathies with an
Sep 24, 2015

Summary Toggle aTyr Pharma Announces Presentations at The World Muscle Congress and 10th International Symposium on Aminoacyl-tRNA Synthetases (AARS2015)

SAN DIEGO , Sept. 24, 2015 / PRNewswire / -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe rare diseases, today announced participation in two upcoming international scientific
Sep 10, 2015

Summary Toggle aTyr Pharma Doses First Patient In Long-Term Safety Extension Study Of Resolaris™ for Treatment of Adult Patients with FSHD
Aug 12, 2015

Summary Toggle aTyr Pharma Announces Second Quarter 2015 Operating Results

Resolaris™ Franchise Expansion on Track for Planned Initiation of Phase 1b/2 Trials in Early Onset Facioscapulohumeral Muscular Dystrophy and Limb-Girdle Muscular Dystrophy SAN DIEGO , Aug. 12, 2015 / PRNewswire / -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in
Jul 20, 2015

Summary Toggle aTyr Pharma Announces Transitions In Clinical Development & Operations

SAN DIEGO, July 20, 2015 /PRNewswire/ -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe rare diseases, today announced that it will transition oversight of clinical development and operations
Jul 13, 2015

Summary Toggle aTyr Pharma Announces Change in Leadership

SAN DIEGO , July 13, 2015 / PRNewswire / -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics to address severe rare diseases, today announced the resignation of President and Chief Operating
Jun 29, 2015

Summary Toggle aTyr Pharma Added To Russell 2000®, 3000® And Global Indexes
Jun 18, 2015

Summary Toggle aTyr Pharma Announces First Quarter 2015 Operating Results

Expands Resolaris™ Franchise: Selects Specific Indication for Phase 1b/2 Trial in Limb-Girdle Muscular Dystrophy SAN DIEGO , June 18, 2015 / PRNewswire / -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of Physiocrine-based therapeutics